Regenerative medicine spoilt for choice

21 April 2011

Current Biology

Embryonic stem cells, induced pluripotent cells, transdifferentiated cells – there is now a wide range of options for medical researchers trying to regenerate disease-affected tissues and organs. But which approach will win the day, and can science policy keep up with the bioethical implications of rapid progress?

View Journal Article / Working Paper

Dr Paul Fairchild and his team from the Oxford Stem Cell Institute are featured in an academic paper in Current Biology.